Grade III rash induced by abemaciclib in a patient with HR+/HER-2 negative breast cancer

Grade III rash induced by abemaciclib in a patient with HR+/HER-2 negative breast cancer

Saved in:

Bibliographic Details
Main Authors:	Yu Yao, Zheng-Cai Zhu, Tao Li, Liang-He Jiao
Format:	Article
Language:	English
Published:	Elsevier 2025-05-01
Series:	Asian Journal of Surgery
Subjects:	Abemaciclib Breast neoplasms Drug eruptions Cyclin-dependent kinase inhibitors Dermatologic toxicities
Online Access:	http://www.sciencedirect.com/science/article/pii/S1015958424027490
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer
by: Ahmad Awada, et al.
Published: (2024-09-01)

Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review
by: N. A. Avxentyev, et al.
Published: (2024-05-01)

Complete Remission of Cutaneous Metastasis from Invasive Breast Cancer with Abemaciclib plus Letrozole
by: Shaunak N. Valame, et al.
Published: (2024-02-01)

Selective cyclin-dependent kinase 4/6 inhibitors as anticancer drugs: Moving beyond hormone receptor-positive breast cancer
by: Tamojit Chaudhuri, et al.
Published: (2019-01-01)

Abemaciclib treatment patterns and outcome in HR+/HER2- locally advanced or metastatic breast cancer: a real-world study from Kuwait and Lebanon
by: Anwar Al Nouri, et al.
Published: (2025-06-01)

Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 − advanced breast cancer: a meta-analysis
by: Isah Adamu Danbala, et al.
Published: (2025-06-01)

Research progress on cell cycle regulation-related molecules in the development of oral squamous cell carcinoma
by: HOU Zeyu, et al.
Published: (2023-04-01)

Real-World Analysis of Adherence to Abemaciclib and Endocrine Therapy in Women with HR+/HER2− Breast Cancer
by: Maria Rosaria Valerio, et al.
Published: (2025-02-01)

Management of Diffuse Carcinomatosis of the Bone Marrow from Occult Breast Cancer with Abemaciclib and Letrozole: Case Report and Literature Review
by: Ketan Makwana, et al.

A real-world study of palbociclib plus endocrine therapy with or without a short course chemotherapy in the first-line treatment of HR-positive HER2-negative metastatic breast cancer
by: Xiangjun Li, et al.
Published: (2025-07-01)

Risk factors for adverse reactions caused by abemaciclib in breast cancer therapy
by: Xianghua Quan, et al.
Published: (2025-06-01)

Abemaciclib in combination with endocrine therapy for the treatment of HR-positive/HER2-negative locally advanced/metastatic breast cancer in the UK: an observational study
by: Judy King, et al.
Published: (2025-07-01)

Complexity in cancer biology: is systems biology the answer?
by: Evangelia Koutsogiannouli, et al.
Published: (2013-04-01)

Case Report: Abemaciclib‐Induced Chronic Renal Failure
by: Lu Lin, et al.
Published: (2025-06-01)

Treatment of luminal HER2-negative breast cancer: opinion of experts
by: E. V. Artemeva, et al.
Published: (2024-06-01)

Abemaciclib and Letrozole in Metastatic Male Breast Cancer
by: Leon Schönfeld, et al.
Published: (2024-11-01)

Real-World, National Study of Palbociclib in HR+/HER2− Metastatic Breast Cancer: A 2.5-Year Follow-Up PALBO01/2021
by: Cristina Marinela Oprean, et al.
Published: (2025-05-01)

HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE
by: L. Yu. Vladimirova, et al.
Published: (2020-06-01)

Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis
by: Rachel M. Layman, et al.
Published: (2025-06-01)

Study of cytostatic and cytotoxic characteristics of modified peptide CDK4/6 inhibitors – functional analogs of p16INK4a (90-97)
by: V. K. Bozhenko, et al.
Published: (2021-01-01)

Drug design for cyclin-dependent kinase 9 (CDK9) inhibitors in silico
by: Kaori Asamitsu, et al.
Published: (2025-06-01)

Ribociclib-induced vitiligo in a case of metastatic carcinoma of the breast
by: Abhira Deb, et al.
Published: (2025-01-01)

Hormone therapy for premenopausal women with metastatic breast cancer: combinations with cyclin-dependent kinase inhibitors
by: E. V. Artamonova, et al.
Published: (2019-09-01)

Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Radiotherapy in Curative Breast Cancer Patients Induced Pneumonitis: A Case Report
by: Pei-Yu Hou
Published: (2025-04-01)

PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
by: N. A. Kozyavin, et al.
Published: (2018-08-01)

Annona squamosa (custard apple) leaves extract mitigates abemaciclib-induced liver injury (AILI) in male rats
by: Lashin S. Ali, et al.
Published: (2025-12-01)

Evolution of systemic treatment for hormone-sensitive breast cancer: from sequential use of single agents to the upfront administration of drug combinations
by: E. N. Imyanitov
Published: (2016-09-01)

Role of p57KIP2 in Stem and Progenitor Leydig Cells of Mouse Testes
by: Seung Hyun Park, et al.
Published: (2025-01-01)

Targeting CDK4/6 suppresses colorectal cancer by destabilizing YAP1
by: Yalei Wen, et al.
Published: (2025-03-01)

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
by: Mashael Algethami, et al.
Published: (2025-08-01)

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
by: Sara M. Tolaney, et al.
Published: (2025-03-01)

Important clinical studies that changed the clinical practice of advanced breast cancer in 2024
by: WU Song, YUAN Yang, JIANG Zefei
Published: (2025-02-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
by: Eric Raspé, et al.
Published: (2017-05-01)

Gut microbiota interact with breast cancer therapeutics to modulate efficacy
by: Alana A Arnone, et al.
Published: (2025-01-01)

Significance and limitations of routine p16/Ki-67 immunohistochemistry as a diagnostic tool for high-grade squamous intraepithelial lesions of the uterine cervix
by: Kazutaka Ozono, et al.
Published: (2025-01-01)

Escalation of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer: to whom, when and why?
by: I. V. Kolyadina
Published: (2024-05-01)

Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
by: Razia Rahman, et al.
Published: (2025-05-01)

THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS
by: S. L. Pavlinsky, et al.
Published: (2017-09-01)

A CDKN2B-Associated Immune Prognostic Model for Predicting Immune Cell Infiltration and Prognosis in Esophageal Carcinoma
by: Peng X, et al.
Published: (2025-04-01)